BioSpace News Archive

Aethlon Medical, Inc. announced that it will issue financial results for the third quarter of fiscal year 2019, ended December 31, 2018, at 4:15 pm eastern time on Monday, February 11, 2019.

Akebia Therapeutics, Inc. granted 11 newly-hired employees options to purchase an aggregate of 41,900 shares of Akebia’s common stock on January 31, 2019, as inducements material to each such employee’s entering into employment with Akebia.

It’s a problem most of us can relate to — clothing material that scratches our skin or causes uncomfortable chafing. That kind of problem is easily solved by changing clothes.

Oxurion NV (Euronext Brussels: OXUR), a biopharmaceutical company developing innovative treatments to preserve vision in patients with diseases affecting the back of the eye, announced today that Patrik De Haes, M.D., chief executive officer, will present a company overview and clinical update at the 2019 BIO CEO & Investor Conference

WellCare Health Plans, Inc. announced it has been notified by the North Carolina Department of Health and Human Services of the state’s intent to award WellCare of North Carolina, Inc.

Actor’s foundation awards grant to conduct clinical trial

BioLineRx Ltd. announced that it has commenced an underwritten public offering of American Depositary Shares, each representing one of its ordinary shares with each ADS to be sold together in a fixed combination with a warrant to purchase ADSs.

Mitsubishi Electric and National Institute of Advanced Industrial Science and Technology collaboration

Agreements with Rutgers and MentiNova for exclusive worldwide rights to issued U.S. patents and pending patent applications Trevi plans Phase 2 trial of nalbuphine ER for LID in patients with Parkinson’s disease in 2019

First-of-its-kind technology advances the ability to detect and analyze exosomes with high sensitivity and specificity